May 20, 2024 · Form 4 insider transaction
Kewalramani Reshma sold 15,202 shares of Vertex Pharmaceuticals Incorporated at $447.00 per share, a transaction worth $6.80M. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 02/07/2024.